2666-6790

Tumour Virus Research

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 119 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact119 DOIs
2

Attach ORCID iDs across 35 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact35 DOIs
3

Deposit reference lists for 14 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact14 DOIs

DOIs for this ISSN

Showing the top 5 of 119 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 HPV and head and neck cancers: Towards early diagnosis and p… (10.1016/j.tvr.2022.200245)
Abstract ORCID
94.88 78
2 Oral human papillomavirus prevalence, persistence, and risk-… (10.1016/j.tvr.2022.200237)
Abstract ORCID
72.36 27
3 Development and evaluation of an online continuing education… (10.1016/j.tvr.2021.200214)
Abstract ORCID
69.90 24
4 Using protection motivation theory to explain the intention… (10.1016/j.tvr.2021.200222)
Abstract ORCID
66.11 20
5 Cervical cancer therapies: Current challenges and future per… (10.1016/j.tvr.2022.200238)
Abstract
65.58 419
6 Harnessing immunity for therapy in human papillomavirus driv… (10.1016/j.tvr.2021.200212)
Abstract ORCID
62.76 17
7 Synonymous nucleotide changes drive papillomavirus evolution (10.1016/j.tvr.2022.200248)
Abstract ORCID
58.80 14
8 Potential entry receptors for human γ-herpesvirus into epith… (10.1016/j.tvr.2021.200227)
Abstract ORCID
57.31 13
9 Polyomavirus large T antigens: Unraveling a complex interact… (10.1016/j.tvr.2024.200306)
Abstract ORCID
57.31 13
10 Human papillomavirus genomics: Understanding carcinogenicity (10.1016/j.tvr.2023.200258)
Abstract
52.93 130
11 Human papillomavirus E6 and E7: What remains? (10.1016/j.tvr.2021.200213)
Abstract
52.76 128
12 Construction of a diagnostic model for hepatitis B-related h… (10.1016/j.tvr.2023.200271)
Abstract
44.98 62
13 Programmed death-ligand 1 (PD-L1) polymorphisms as predictiv… (10.1016/j.tvr.2022.200249)
Abstract ORCID
42.25 6
14 The human Papillomavirus twilight zone – Latency, immune con… (10.1016/j.tvr.2023.200268)
Abstract
42.03 47
15 Merkel cell polyomavirus and associated Merkel cell carcinom… (10.1016/j.tvr.2021.200232)
Abstract
41.09 43
16 Epstein-Barr virus: Current questions and challenges (10.1016/j.tvr.2021.200218)
Abstract
40.05 39
17 Does the number of doses matter? A qualitative study of HPV… (10.1016/j.tvr.2021.200217)
Abstract ORCID
38.91 5
18 Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) a… (10.1016/j.tvr.2023.200256)
Abstract ORCID
38.91 5
19 Opportunities to advance cervical cancer prevention and care (10.1016/j.tvr.2024.200292)
Abstract ORCID
38.91 5
20 HPV16 and HPV18 type-specific APOBEC3 and integration profil… (10.1016/j.tvr.2021.200221)
Abstract
36.18 27
21 Corrigendum to CINtec PLUS and cobas HPV testing for triagin… (10.1016/j.tvr.2021.200215)
Abstract References ORCID
35.78 2
22 Almost famous: Human adenoviruses (and what they have taught… (10.1016/j.tvr.2021.200225)
Abstract
34.95 24
23 Exploring monitoring strategies for population surveillance… (10.1016/j.tvr.2023.200255)
Abstract ORCID
34.95 4
24 Diversity of cervicovaginal human papillomavirus (HPV) genot… (10.1016/j.tvr.2023.200261)
Abstract ORCID
34.95 4
25 Identification and characterisation of novel potential phosp… (10.1016/j.tvr.2023.200270)
Abstract ORCID
34.95 4
26 Interplay between the DNA damage response and the life cycle… (10.1016/j.tvr.2023.200272)
Abstract
34.51 23
27 Small DNA tumor viruses and human cancer: Preclinical models… (10.1016/j.tvr.2022.200239)
Abstract
33.56 21
28 Kaposi's sarcoma-associated herpesvirus at 27 (10.1016/j.tvr.2021.200223)
Abstract
31.97 18
29 The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) a… (10.1016/j.tvr.2022.200246)
Abstract
31.38 17
30 Clinical indications for host-cell DNA methylation markers i… (10.1016/j.tvr.2024.200308)
Abstract
31.38 17
31 Increasing HPV vaccination coverage to prevent oropharyngeal… (10.1016/j.tvr.2021.200234)
Abstract
30.10 15
32 Provider preferences for anal cancer prevention screening: R… (10.1016/j.tvr.2022.200235)
Abstract
30.10 15
33 Human papillomavirus seroprevalence and seroconversion follo… (10.1016/j.tvr.2022.200236)
Abstract
30.10 15
34 Detection of high-risk HPV in FFPE specimens of various tumo… (10.1016/j.tvr.2022.200243)
Abstract ORCID
30.10 3
35 DNA methylation at individual CpG-sites of EPB41L3, HTERT an… (10.1016/j.tvr.2024.200288)
Abstract ORCID
30.10 3
36 Differences in integration frequencies and APOBEC3 profiles… (10.1016/j.tvr.2022.200247)
Abstract
29.40 14
37 HPV16 genome structure analysis in oropharyngeal cancer PDXs… (10.1016/j.tvr.2024.200285)
Abstract
29.40 14
38 Effective HPV vaccination coverage in Australia by number of… (10.1016/j.tvr.2021.200216)
Abstract
27.85 12
39 Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways… (10.1016/j.tvr.2022.200244)
Abstract
27.85 12
40 Elevated iNOS and 3′-nitrotyrosine in Kaposi's Sarcoma tumor… (10.1016/j.tvr.2023.200259)
Abstract
27.85 12
41 Tegument proteins of Epstein-Barr virus: Diverse functions,… (10.1016/j.tvr.2023.200260)
Abstract
27.85 12
42 How can HPV E6 manipulate host cell differentiation process… (10.1016/j.tvr.2025.200313)
Abstract
27.85 12
43 Modulation of epithelial homeostasis by HPV using Notch and… (10.1016/j.tvr.2024.200297)
Abstract
26.98 11
44 Juvenile onset recurrent respiratory papillomatosis: What do… (10.1016/j.tvr.2024.200281)
Abstract
26.03 10
45 The impact of DNA tumor viruses in low-to-middle income coun… (10.1016/j.tvr.2024.200289)
Abstract
26.03 10
46 Drugs and drug targets for the treatment of HPV-positive cer… (10.1016/j.tvr.2024.200309)
Abstract
26.03 10
47 Oesophageal carcinoma: The prevalence of DNA tumour viruses… (10.1016/j.tvr.2021.200231)
Abstract
25.00 9
48 Methyltransferase-independent function of enhancer of zeste… (10.1016/j.tvr.2023.200264)
Abstract
25.00 9
49 Analytical validation and diagnostic performance of the ASCL… (10.1016/j.tvr.2023.200275)
Abstract
25.00 9
50 Epstein-Barr Virus miR-BARTs 7 and 9 modulate viral cycle, c… (10.1016/j.tvr.2023.200276)
Abstract
25.00 9